Healthcare companies and projects
Explore healthcare companies and projects across pharmaceuticals, biotechnology, medical equipment, care services and health-data infrastructure. Browse public profiles and the evaluations available on Orbitrum, then discover the experts behind the research.
Projects in Healthcare
Stage
All stages
4,357 projects
AlmirallAlmirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.Web2
Almoosa HealthAlmoosa Health Company operates as a private healthcare provider in the Kingdom of Saudi Arabia. It stores medical items and sells medicine, cosmetics, and disposable medical items. The company also operates specialist and rehabilitation hospitals, medical and emergency centers, pharmacies, mental health clinics, and oncology centers, as well as a college of health sciences. Its medical specialties include pain management, lymphatic massage, hyperbaric oxygen therapy, occupational therapy, speech and language disorders, personality and behavioral disorders, supportive devices and prosthetics, urology, ophthalmic surgery, general surgery, otolaryngology (ear, nose, and throat), wound care, emergency medicine, audiology, rheumatology, allergy and immunology, health education, angiography and interventional radiology, infectious diseases, chest diseases, dermatology, internal medicine, pediatrics, dentistry, nephrology, endocrinology, gastroenterology, pediatric neurology, physiotherapy, psychiatry, bone and joint surgery, psychiatric rehabilitation, therapeutic nutrition, and vascular medicine. The company was formerly known as Al Moosa Specialist Hospital and changed its name to Almoosa Health Company in February 2024. The company was incorporated in 1996 and is based in Al Mubarraz, the Kingdom of Saudi Arabia. Almoosa Health Company operates as a subsidiary of Abdulaziz bin Abdullah Almoosa Investment Company.Web2
Alpha Tau MedicalAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.Web2
AlphamabAlphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People’s Republic of China.Web2Learn how to assess projects in this field with Orbitrum Academy.
About this sector
Healthcare includes both medical businesses and projects supporting how health information or research is managed. Its application sub-sectors cover pharmaceuticals, biotechnology and medical research, healthcare equipment and providers, medical records, research transparency, supply-chain transparency and patient-data privacy.
How to compare projects
A drug developer, a device supplier, a care provider and a health-data project have different activities. Use the sub-sector to establish that context, then read the actual evaluation rather than assuming a score describes every aspect of the business. This collection is for project research, not for choosing a medical treatment.
Projects follow the categories assigned in the Orbitrum application. This collection supports research and discovery; it is not an investment ranking.
Industry definitions
Healthcare Equipment & Supplies (1,090)
Suppliers of healthcare equipment and related supplies.
Pharmaceuticals (1,515)
Companies classified specifically in pharmaceuticals.
Biotechnology & Medical Research (1,179)
Companies and projects focused on biotechnology or medical research.
Healthcare Providers & Services (573)
Organizations providing healthcare or related services.
Questions to guide your research
- What product, service or health-data function does the project provide?
- Which development or operating milestones are documented in the profile and research?
- What evidence and limitations does the author discuss?
Questions about this sector
Does this sector include biotechnology and medical devices?
Yes. The current application classification includes biotechnology and medical research, pharmaceuticals, healthcare equipment and supplies, and healthcare services and medical devices. The list below reflects the categories available in Orbitrum.
How can I find healthcare experts?
Open the authors attached to published evaluations or analysis of these projects. Their profiles show the work available on Orbitrum; a project category alone does not establish an author's medical qualifications.
